Recursion Pharmaceuticals
AI-native drug discovery — watch only, heavy losses and insiders not buying per May playbook.
$3.52
+0.57%
Short interest
Short % of float
28.9%
Days to cover
4.4d
Shares short
161.93M
Vs Sep 15
-9%
Crowded short. If this turns, covering has to buy a large slice of the float.
No clear read
No fundamentals red flag, but no technical discount either — not enough signal here to call this distressed or contrarian.
Share count and days to cover are the latest FINRA settlement. Short % of float is from Finviz. Prints land about twice a month — fuel for a turn, not today's flow.
No upcoming events in tracker — Finnhub may add earnings when scheduled
Next report
2027-02-23 · Q4 2026
EPS est. -0.23 · actual -0.22 (+5.5%)
Last reported · 2026-09-30
Last surprise +5.5% vs estimate
Insider trades (Form 4)
Buys
189,643 sh
$700K
Sells
278,302 sh
$1.1M
Net (12 filings)
-88,659 sh
$400K net
Borgeson Blake (Open-market sale) — 40,000 sh · $0.2M
Hassan Fred (Stock award / grant) — 156,658 sh · $0.6M
Borgeson Blake (Open-market sale) — 50,000 sh · $0.2M
HERSHBERG ROBERT (Option exercise) — 25,000 sh · $0.1M
HERSHBERG ROBERT (Open-market sale) — 25,000 sh · $0.1M
HERSHBERG ROBERT (Option exercise) — 25,000 sh · $0.1M
Dar Zavain (Stock award / grant) — 4,607 sh · $0.0M
Li Dean Y (Stock award / grant) — 3,378 sh · $0.0M
Taylor Ben R (Tax withholding) — 5,396 sh · $0.0M
Khan Najat (Open-market sale) — 22,408 sh · $0.1M
Borgeson Blake (Open-market sale) — 30,000 sh · $0.1M
Khan Najat (Tax withholding) — 80,498 sh · $0.3M
RSI, moving averages, MACD, Bollinger bands & candlestick patterns from Yahoo daily data — verify on chart
Below 20-day MA
Price $3.52 vs 20 SMA $3.81
Below 50-day MA
Price $3.52 vs 50 SMA $3.77
Above 200-day MA
Price $3.52 vs 200 SMA $3.50
Below 251-day high
-29.0% from 251-day high ($4.96)
Above 251-day low
23.9% above 251-day low ($2.84)
Gap up
Opened 2.4% above prior close on 2026-11-06
Price vs 200-day EMA, plus whether profit shows up as cash. Cash flow, cash, capex growth, and interest coverage sit next to the multiple.
4.6% below 200-day EMA
Neither a technical discount nor a fundamentals red flag right now.
Trailing PE
—
Invest rank
30
Swing rank
50
Earnings skew
open
Cash flow/share
−$1.38
Trailing twelve months
Cash/share
$0.98
Latest quarter
Interest cover
-63.8x
Operating profit / interest
Price / FCF
—
After capex
Rev / share
46.9%
Five-year revenue growth per share
Capex growth
2.1%
5-year rate
Gross margin
29.2%
Prior year 5.0%
Revenue growth
56.2%
YoY, TTM or latest quarter
Net margin
-697.1%
TTM profitability
Debt / equity
1.3%
Lower = less leveraged
FCF growth
—
5Y CAGR, capex-aware
Composite fundamentals score: 42/100 · from Finnhub basic financials, verify against the latest 10-Q before acting.